#United States #New York #Levi & Korsinsky #Inc. #securities lawsuit #BioAge Labs

Important Notice for BioAge Labs Shareholders

Investors holding shares in BioAge Labs, Inc. (NASDAQ: BIOA) should be aware of a significant legal development affecting their investments. Levi & Korsinsky, LLP has issued a notification regarding a class action securities lawsuit. This notice serves as a crucial alert for those who purchased shares during the company's initial public offering on or around September 26, 2024.

Overview of the Class Action Lawsuit

The lawsuit aims to recover losses incurred by investors allegedly impacted by securities fraud. Specifically, the focus is on those stockholders who bought shares following BioAge's IPO and later faced a dramatic decline in stock value. Following the company's announcement on December 6, 2024, regarding the suspension of the STRIDES Phase 2 trial for its leading product candidate, azelaprag, significant safety concerns arose. This news was an unexpected blow to investors who were encouraged by previous disclosures about azelaprag's potential benefits for patients undergoing obesity therapy with incretin medications.

Impact on Stock Value

On the day of the announcement, BioAge's stock plummeted from $20.09 to $4.65 per share within just 24 hours. Such a drastic fall raises serious questions about the information provided to investors prior to the IPO and highlights the complexities surrounding the company's communication and transparency regarding its drug trials.

How to Participate

For those who have experienced financial losses during the relevant investment period, the opportunity to act is limited. Affected investors are advised to reach out to Levi & Korsinsky before the deadline of March 10, 2025, to potentially take on the role of lead plaintiff in the case. However, it is essential to note that being named as a lead plaintiff is not a requirement to participate in any potential recovery following the lawsuit.

No Financial Risk Involved

It's worth mentioning that any investor who qualifies as a class member lawyer has the possibility of benefit without incurring out-of-pocket expenses. Levi & Korsinsky has assured that there will be no cost or obligation for those participating, making it an accessible option for many stakeholders.

Levi & Korsinsky's Track Record

With a reputation forged over two decades, Levi & Korsinsky has successfully represented numerous investors in high-stakes securities litigation. Their firm has earned recognition for securing substantial compensations for clients and has consistently ranked among the top securities litigation firms in the United States according to ISS Securities Class Action Services.

Contact Information

Investors looking for more information regarding this class action should consider contacting the firm directly. Joseph E. Levi, Esq., and Ed Korsinsky, Esq. are leading the efforts from their New York office, and they are readily available to assist potential clients at (212) 363-7500 or via email at [email protected]

Conclusion

The course of action recommended for BioAge Labs investors is critical in ensuring their rights and potential recovery from recent losses. As the deadline approaches, those affected should take swift action by contacting Levi & Korsinsky. Protecting investor rights and seeking justice in the face of alleged fraud remains a top priority for many, including the dedicated legal teams ready to assist.